Bora Pharmaceuticals to Expand Midwest Manufacturing Site 

Bora Pharmaceuticals Co., Ltd., a global pharmaceutical manufacturer, is making significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, MN. Bora acquired the site in 2024 as part of its $210 million acquisition of Upsher-Smith Laboratories, expanding its U.S. manufacturing footprint.

As the entity separation from Upsher-Smith Laboratories takes effect on August 5, Bora continues to experience growing demand for oral solid dose (OSD) development and manufacturing with increasingly complex formulations, new drug delivery technologies, and shift of biologics into OSD formats. Bora has already secured multiple contracts for development and commercial supply of advanced OSD programs.

The first phase of investment will add a Gerteis Macro-Pactor at the site, to be installed and operational 3Q25. This includes a broader buildout of 100,000 sq.-ft. of dedicated shell space designed to streamline production for partners with high-volume needs. 

The facility offers on-site quality control labs and a dedicated development team to support product and analytical development. It’s an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance.

“With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,” said J.D. Mowery, president of Bora’s CDMO business. “Bora’s Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing.”